{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hypertension&page=96",
    "query": {
      "condition": "Hypertension",
      "page": 96
    },
    "page_size": 10
  },
  "pagination": {
    "page": 96,
    "page_size": 10,
    "total_count": 3919,
    "total_pages": 392,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hypertension&page=97&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hypertension&page=95&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T03:54:16.235Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00834171",
      "title": "A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Loteprednol etabonate ophthalmic suspension 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol etabonate (0.5%) and tobramycin (0.3%).",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2009-01",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2011-09-26",
      "last_synced_at": "2026-11-08T03:54:16.235Z",
      "location_count": 1,
      "location_summary": "Maclean, Virginia",
      "locations": [
        {
          "city": "Maclean",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00834171"
    },
    {
      "nct_id": "NCT00642434",
      "title": "Comparison of Blood Pressure Medications on Metabolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "carvedilol",
          "type": "DRUG"
        },
        {
          "name": "metoprolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "45 Years to 85 Years"
      },
      "enrollment_count": 22,
      "start_date": "2004-01",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2023-12-26",
      "last_synced_at": "2026-11-08T03:54:16.235Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00642434"
    },
    {
      "nct_id": "NCT07288398",
      "title": "LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Hypertension Associated With HFpEF"
      ],
      "interventions": [
        {
          "name": "TNX-103",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tenax Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 540,
      "start_date": "2026-03-03",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-08T03:54:16.235Z",
      "location_count": 45,
      "location_summary": "Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07288398"
    },
    {
      "nct_id": "NCT00853957",
      "title": "Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Aliskiren/Amlodipine",
          "type": "DRUG"
        },
        {
          "name": "Amlodipine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 443,
      "start_date": "2009-02",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2012-04-30",
      "last_synced_at": "2026-11-08T03:54:16.235Z",
      "location_count": 9,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Oxon Hill, Maryland + 6 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Oxon Hill",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Trenton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853957"
    },
    {
      "nct_id": "NCT03739034",
      "title": "Evaluation of a Lifestyle Medicine Practice",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Lifestyle Related Disease",
        "Diabetes",
        "Overweight and Obesity",
        "Dyslipidemias",
        "Hypertension",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Lifestyle Medicine",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Ohio University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2018-06-28",
      "completion_date": "2022-03-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-10",
      "last_synced_at": "2026-11-08T03:54:16.235Z",
      "location_count": 1,
      "location_summary": "Athens, Ohio",
      "locations": [
        {
          "city": "Athens",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03739034"
    },
    {
      "nct_id": "NCT02966665",
      "title": ": Vascular Function in Health and Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Pulmonary Artery Hypertension",
        "Heart Failure",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Maximum Exercise Tests",
          "type": "OTHER"
        },
        {
          "name": "BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate",
          "type": "DRUG"
        },
        {
          "name": "BQ-123",
          "type": "DRUG"
        },
        {
          "name": "Fexofenadine, Ranitidine",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin-II, Valsartan",
          "type": "OTHER"
        },
        {
          "name": "Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine",
          "type": "DRUG"
        },
        {
          "name": "BQ-123, MitoQ, BH4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "D. Walter Wray",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2008-09",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-08T03:54:16.235Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02966665"
    },
    {
      "nct_id": "NCT02059811",
      "title": "Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "DASH Diet",
          "type": "OTHER"
        },
        {
          "name": "Control Diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2014-02",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-10-03",
      "last_synced_at": "2026-11-08T03:54:16.235Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02059811"
    },
    {
      "nct_id": "NCT04327934",
      "title": "Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "GnRH antagonist",
          "type": "DRUG"
        },
        {
          "name": "GnRH antagonist + MethylTESTOSTERone 5 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2017-12-01",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-02-02",
      "last_synced_at": "2026-11-08T03:54:16.235Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04327934"
    },
    {
      "nct_id": "NCT00547300",
      "title": "Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-release (ER) for Hypertension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Metoprolol ER",
          "type": "DRUG"
        },
        {
          "name": "Nebivolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 49,
      "start_date": "2007-10-31",
      "completion_date": "2008-01-02",
      "has_results": true,
      "last_update_posted_date": "2019-05-21",
      "last_synced_at": "2026-11-08T03:54:16.235Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00547300"
    },
    {
      "nct_id": "NCT06886087",
      "title": "Assessment of Risks of Perinephric Fat Thickness to Adverse Renal Outcomes Post Donor Nephrectomy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Living Kidney Donation",
        "Hypertension",
        "Nephrectomy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-02-10",
      "completion_date": "2028-02-10",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-11-08T03:54:16.235Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06886087"
    }
  ]
}